These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 24939178)
21. Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer. Huang EC; Chen G; Baek SJ; McEntee MF; Collier JJ; Minkin S; Biggerstaff J; Whelan J Nutr Cancer; 2011 Nov; 63(8):1287-96. PubMed ID: 21958043 [TBL] [Abstract][Full Text] [Related]
22. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells. Lee J; Ju J; Park S; Hong SJ; Yoon S Nutr Cancer; 2012; 64(1):153-62. PubMed ID: 22098108 [TBL] [Abstract][Full Text] [Related]
24. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694 [TBL] [Abstract][Full Text] [Related]
25. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Girnita L; Worrall C; Takahashi S; Seregard S; Girnita A Cell Mol Life Sci; 2014 Jul; 71(13):2403-27. PubMed ID: 24276851 [TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory effect of Marchantin M contributes to sensitization of prostate cancer cells to docetaxel. Niu L; Deng J; Zhu F; Zhou N; Tian K; Yuan H; Lou H Cancer Lett; 2014 Jun; 348(1-2):126-34. PubMed ID: 24680871 [TBL] [Abstract][Full Text] [Related]
28. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383 [TBL] [Abstract][Full Text] [Related]
29. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Fabbri F; Brigliadori G; Carloni S; Ulivi P; Tesei A; Silvestrini R; Amadori D; Zoli W Prostate; 2010 Feb; 70(2):219-27. PubMed ID: 19790230 [TBL] [Abstract][Full Text] [Related]
31. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
33. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904 [TBL] [Abstract][Full Text] [Related]
34. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Nair PN; De Armond DT; Adamo ML; Strodel WE; Freeman JW Oncogene; 2001 Dec; 20(57):8203-14. PubMed ID: 11781836 [TBL] [Abstract][Full Text] [Related]
35. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Sroka IC; McDaniel K; Nagle RB; Bowden GT Prostate; 2008 Apr; 68(5):463-76. PubMed ID: 18196535 [TBL] [Abstract][Full Text] [Related]
36. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328 [TBL] [Abstract][Full Text] [Related]
37. EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin. Maslova K; Kyriakakis E; Pfaff D; Frachet A; Frismantiene A; Bubendorf L; Ruiz C; Vlajnic T; Erne P; Resink TJ; Philippova M FASEB J; 2015 Feb; 29(2):494-507. PubMed ID: 25381040 [TBL] [Abstract][Full Text] [Related]
38. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
39. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. Shukla S; Mishra A; Fu P; MacLennan GT; Resnick MI; Gupta S FASEB J; 2005 Dec; 19(14):2042-4. PubMed ID: 16230333 [TBL] [Abstract][Full Text] [Related]
40. Interruption of mitochondrial complex IV activity and cytochrome c expression activated O₂·⁻-mediated cell survival in silibinin-treated human melanoma A375-S2 cells via IGF-1R-PI3K-Akt and IGF-1R-PLC γ-PKC pathways. Jiang YY; Huang H; Wang HJ; Wu D; Yang R; Tashiro S; Onodera S; Ikejima T Eur J Pharmacol; 2011 Oct; 668(1-2):78-87. PubMed ID: 21703257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]